• 1
    Tzioufas T, Youinou P, Moutsopoulos HM. Sjögren's syndrome. In: MaddisonPJ, IsenbergDA, WooP, GlassDN, editors. Oxford textbook of rheumatology. 2nd ed. Oxford: Oxford Medical Publications; 1997. p. 130117.
  • 2
    Fox RI, Kang HI. Pathogenesis of Sjögren's syndrome. Rheum Dis Clin North Am 1992; 18: 51738.
  • 3
    Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome. Arthritis Rheum 2000; 43: 164754.
  • 4
    Haddad EB, Rousel J, Lindsay MA, Barnes PJ. Synergy between TNF-α and IL-1β in inducing transcriptional down-regulation of muscarinic M2 receptor gene expression: involvement of protein kinase A and ceramide pathways. J Biol Chem 1996; 271: 3258692.
  • 5
    Fox RI, Kang HI, Ando D, Abrams J, Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. J Immunol 1994; 152: 55329.
  • 6
    Koski H, Janin A, Humphreys-Beher MG, Sorsa T, Malmstrom M, Konttinen YT. Tumor necrosis factor-α and receptors for it in labial salivary glands in Sjögren's syndrome. Clin Exp Rheumatol 2001; 19: 1317.
  • 7
    Matsumura R, Umemiya K, Goto T, Nakazawa T, Ochiai K, Kagami M, et al. Interferon γ and tumor necrosis factor α induce Fas expression and anti-Fas mediated apoptosis in a salivary ductal cell line. Clin Exp Rheumatol 2000; 18: 3118.
  • 8
    Azuma M, Aota K, Tamatani T, Motegi K, Yamashita T, Harada K, et al. Suppression of tumor necrosis factor α-induced matrix metalloproteinase 9 production by the introduction of a super-repressor form of inhibitor of nuclear factor κBα complementary DNA into immortalized human salivary gland acinar cells: prevention of the destruction of the acinar structure in Sjögren's syndrome salivary glands. Arthritis Rheum 2000; 43: 175667.
  • 9
    Cuello C, Palladinetti P, Tedla N, Girolamo N, Lloyd AR, McCluskey PJ, et al. Chemokine expression and leukocyte infiltration in Sjögren's syndrome. Br J Rheumatol 1998; 37: 77983.
  • 10
    Mariette X. Current and potential treatments for primary Sjögren's syndrome. Joint Bone Spine 2002; 69: 3636.
  • 11
    Tornwall J, Fox H, Edwards C, Fox R. Treatment with pegylated recombinant methionyl human soluble tumor necrosis factor-type 1 receptor prevents development of Sjögren's syndrome and diabetes in the NOD mouse model [abstract]. Arthritis Rheum 1999; 42 Suppl 9: S403.
  • 12
    Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum 2001; 44: 23715.
  • 13
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 5548.
  • 14
    Perneger TV, Leplege A, Etter JF, Rougemont A. Validation of a French-language version of the MOS 36-item Short Form health survey (SF-36) in young healthy adults. J Clin Epidemiol 1995; 48: 105160.
  • 15
    Abel U, Koch A. The role of randomization in clinical studies: myths and beliefs. J Clin Epidemiol 1999; 52: 48797.
  • 16
    Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 188792.
  • 17
    Zandbelt MM, De Wilde PCM, van Damme PA, Hoyng C, van de Putte LBA, van den Hoogen FHJ. Etanercept in the treatment of primary Sjögren's syndrome: a pilot study [abstract]. Ann Rheum Dis 2003; 62 Suppl 1: OP0057.
  • 18
    De Rycke L, Kruithof E, van Damme N, Hoffman IE, van den Bossche N, van den Bosch F, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003; 48: 101523.
  • 19
    Batten M, Fletcher C, Ng LG, Groom J, Wheway J, Laabi Y, et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 2004; 172: 81222.